drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (CAR-T)
drug_description
Autologous CAR-T cells engineered to target the immune checkpoint ligand B7-H3 (CD276), promoting T-cell activation and cytotoxicity against B7-H3–positive solid tumors upon reinfusion.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a chimeric antigen receptor that binds B7-H3 (CD276) on tumor cells. Antigen engagement triggers CD3 zeta and costimulatory signaling in an MHC-independent manner, driving T-cell activation, proliferation, cytokine release, and cytotoxic killing of B7-H3-positive solid tumor cells.
drug_name
B7-H3 (CD276)-directed CAR-T cells
nct_id_drug_ref
NCT06515626